EUVIMEDEUVIMED entdecken
Open Access

Lung cancer screening in Lithuania: a cost-effectiveness analysis

Hilde Ten Berge, Greta Piazza, Dianne Ramaker, Xuanqi Pan, Titas Bukšnys, Saulius Cicėnas, Skaidrius Miliauskas, Giedre Smailyte, Rolandas Zablockis, Marius Zemaitis, Edvardas Danila

Journal of Comparative Effectiveness Research · 2026-08 · 15 (8)

DOI: 10.57264/cer-2026-0034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-08. Verfasst von Hilde Ten Berge und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Diagnostic Accuracy, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Lung Neoplasms, Early Detection of Cancer, Tomography, X-Ray Computed, Mass Screening. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study aimed to assess the cost-effectiveness of the annual volumetric-enabled low-dose computed tomography (LDCT) lung cancer screening (LCS), based on the NELSON screening outcomes, versus no screening for the asymptomatic high-risk population in Lithuania. Materials & methods: The previously established model with a decision tree with an integrated state-transition Markov trace was adapted to assess the health benefits and the financial consequences of LCS from the Lithuanian healthcare system perspective. Individuals aged 50–74 years and with a smoking history underwent LCS with LDCT in the screening arm, and it was compared with the absence of screening across a lifetime horizon. The primary outcomes included the clinical benefits (lung cancer cases detected per stage and premature lung cancer deaths averted), direct costs (recruitment, diagnostic and treatment costs) of LCS implementation, quality-adjusted life years, life-years and the incremental cost-effectiveness ratio. One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to ascertain the result's robustness.

Results

Annual LCS with volumetric-enabled LDCT for 170,808 eligible individuals in Lithuania resulted in 6117 additional early-stage (I and II) lung cancers detected and 1874 averted late-stage (III and IV) lung cancers, leading to 2606 premature lung cancer deaths averted and 21,639 life-years gained at an uptake rate of 46.5%. The incremental cost-effectiveness ratio was €1372 per quality-adjusted life year with incremental costs of €21.1 million and 15,391 quality-adjusted life years gained. The results were robust based on sensitivity and scenario analyses.

Conclusion

This study demonstrated that annual LCS with volumetric-enabled LDCT for a high-risk population could be cost-effective compared with no screening in Lithuania.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsEarly Detection of CancerTomography, X-Ray ComputedMass ScreeningHumansLithuaniaCost-Effectiveness AnalysisCost-Benefit AnalysisMiddle AgedAgedQuality-Adjusted Life YearsFemaleMaleMarkov Chains

Stichwörter der Autor:innen

Markov modelcomputed tomographycost-effectivenessearly detectionlung cancer screening

Autor:innen und Institutionen

  • Institute for Diagnostic Accuracy, Groningen, The Netherlands.
  • Unit of Global Health, Faculty of Medical Sciences, University of Groningen, Groningen, The Netherlands.
  • Market Access Department, AstraZeneca, Vilnius, Lithuania.
  • Department of Thoracic Surgery & Oncology, National Cancer Institute, Vilnius, Lithuania.
  • Department of Pulmonology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • National Cancer Institute, Laboratory of Cancer Epidemiology, Vilnius, Lithuania.

Zitieren

APA

Berge, H. T., Piazza, G., Ramaker, D., Pan, X., Bukšnys, T., Cicėnas, S., Miliauskas, S., Smailyte, G., Zablockis, R., Zemaitis, M., & Danila, E. (2026). Lung cancer screening in Lithuania: a cost-effectiveness analysis. Journal of Comparative Effectiveness Research, 15(8). https://doi.org/10.57264/cer-2026-0034

Vancouver

Berge HT, Piazza G, Ramaker D, Pan X, Bukšnys T, Cicėnas S, et al. Lung cancer screening in Lithuania: a cost-effectiveness analysis. Journal of Comparative Effectiveness Research. 2026;15(8). doi:10.57264/cer-2026-0034

BibTeX
@article{Berge2026,
  author = {Berge, Hilde Ten and Piazza, Greta and Ramaker, Dianne and Pan, Xuanqi and Bukšnys, Titas and Cicėnas, Saulius and Miliauskas, Skaidrius and Smailyte, Giedre and Zablockis, Rolandas and Zemaitis, Marius and Danila, Edvardas},
  title = {Lung cancer screening in Lithuania: a cost-effectiveness analysis},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  volume = {15},
  number = {8},
  doi = {10.57264/cer-2026-0034}
}
Kostenlos starten →